Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5381 in chronic heart failure with reduced ejection fraction
NCT06237309Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of REGN5381 in heart failure with reduced ejection fraction (HFrEF), sponsored by Regeneron Pharmaceuticals. Started Apr 2024; status: terminated.
02
Drugs
REGN5381
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06237309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237309.